Cost-Effectiveness of Sibutramine in the Treatment of Obesity
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Background. This study reports incremental cost-utility of sibutramine compared to diet and lifestyle advice for the treatment of obesity. Method. The model estimates the costs and quality of life benefits associated with weight loss itself and the reduced incidence of coronary heart disease (CHD) and diabetes in the “healthy obese.” The key source of effectiveness data is 2 randomized controlled trials over 12 months. Utility gain per kilogram lost is analyzed using Short Form–36 data from sibutramine trials. The impact on CHD is estimated using the Framingham risk equation, which relates age/sex/body mass index to risk of heart disease. The reduced incidence of diabetes due to weight loss is estimated from published literature. A life tables approach was used to calculate the cost per quality-adjusted life year (QALY) of 1 year’s treatment with sibutramine compared to diet and lifestyle advice. Results. The incremental cost per QALY of sibutramine is £4780. Sensitivity analyses show that this result is sensitive to utility associated with weight loss and the frequency of monitoring.Conclusions. Sibutramine is a costeffective treatment for obesity when combined with diet and lifestyle advice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Weight gain as a risk factor for clinical diabetes mellitus in women
Colditz, G. A., Willett, W. C., Rotnitzky, A., & Manson, J. E. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-7-199504010-00001 · Cited by 2,064
An updated coronary risk profile. A statement for health professionals.
Anderson, K. M., Wilson, P. W., Odell, P. M., & Kannel, W. B. (1991) · Circulation · doi:10.1161/01.cir.83.1.356 · Cited by 1,834
Obesity, Fat Distribution, and Weight Gain as Risk Factors for Clinical Diabetes in Men
Chan, J. M., Rimm, E. B., Colditz, G. A., Stampfer, M. J., & Willett, W. C. (1994) · Diabetes Care · doi:10.2337/diacare.17.9.961 · Cited by 1,808
Variations in population health status: results from a United Kingdom national questionnaire survey
Kind, P., Dolan, P., Gudex, C., & Williams, A. (1998) · BMJ · doi:10.1136/bmj.316.7133.736 · Cited by 1,059 · cited 2×
“Life years were transformed into QALYs by using age-adjusted utility scores adapted from Kind and others.(18) It was assumed that a nonfatal CHD event incurs a significant reduction in quality of life.”
MethodEffect of sibutramine on weight maintenance after weight loss: a randomised trial
James, W. P. T., Astrup, A., Finer, N., Hilsted, J., Kopelman, P., Rössner, S., Saris, W. H. M., & Gaal, L. F. V. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03491-7 · Cited by 817
Cited by
Picot, J., Jones, J., Colquitt, J., Gospodarevskaya, E., Loveman, E., Baxter, L., & Clegg, A. (2009) · Health Technology Assessment · doi:10.3310/hta13410 · Cited by 1,066
Loveman, E., Frampton, G., Shepherd, J., Picot, J., Cooper, K., Bryant, J., Welch, K., & Clegg, A. (2011) · Health Technology Assessment · doi:10.3310/hta15020 · Cited by 296
Gordon, L., Graves, N., Hawkes, A., & Eakin, E. (2007) · Chronic Illness · doi:10.1177/1742395307081732 · Cited by 77
Metadata
- Authors
- Warren, E., Brennan, A., & Akehurst, R.
- Venue
- Medical Decision Making
- Publisher
- SAGE Publications
- Published
- 2004-01
- Volume
- 24
- Issue
- 1
- Pages
- 9-19
- ISSN
- 0272-989X (ISSN-L)
- 1552-681X
- OpenAlex
- W2138604642
- Cited by
- 42
- References
- 5
- FWCI
- 3.13
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cost-Effectiveness of Sibutramine in the Treatment of Obesity. https://app.cochat.ai/papers/10.1177/0272989x03261565
- The paper
- Warren, E., Brennan, A., & Akehurst, R. (2004). Cost-Effectiveness of Sibutramine in the Treatment of Obesity. Medical Decision Making. https://doi.org/10.1177/0272989x03261565
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.